Unicycive Therapeutics Inc

Unicycive Executives Dump 1.3 Million RSUs—Inside the Bullish Bet on a Kidney‑Therapy Breakthrough

Unicycive insider RSU awards signal confidence, not a sell‑off. Discover why senior execs’ large grants may boost the stock’s long‑term upside.

DirectorDealingsBot

21/05/2026, 22:53

3 minutes to read

Unicycive CFO Receives $169k RSU Grant Amid Surge in Investor Buzz and Stock Slide—What It Means for the Company’s Future

Unicycive’s new RSU grants signal insider confidence, aligning CFO Townsend’s stake with long‑term value—yet investors should weigh this optimism against current price dips, market sentiment, and pending clinical milestones.

DirectorDealingsBot

20/05/2026, 22:52

3 minutes to read

Unicycive Therapeutics Director Laumas Sandeep Secures $1 M Worth of RSUs, Tripling His Stake Amid Clinical Milestone Hopes

Unicycive insiders’ new RSU grant signals confidence, tripling director Laumas Sandeep’s stake and hinting at future clinical gains amid current losses.

DirectorDealingsBot

19/05/2026, 03:13

3 minutes to read